Latest Hydrix (ASX:HYD) News

Capital moves, contract wins and AI product pushes drove a busy week across small and mid-cap technology stocks. Hydrix, Complii and ClearVue led the board, while investors sold names where early excitement gave way to dilution concerns or softer earnings detail.

Hydrix Limited has bolstered its balance sheet by raising $3.89 million and converting $5.1 million of debt into equity, positioning itself to expand its Defence technology footprint following a $1.2 million contract with NIOA Group.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

A volatile week for ASX tech saw a steep sell-off in freight software, while defence AI and RegTech contract wins pulled buyers back into smaller names. Big corporate actions kept attention on what’s real: signed deals, cash timelines, and who pays whom, and when.

Hydrix Limited has amended its quarterly cash flow report, revealing stronger customer receipts and a stable cash position supported by robust financing facilities.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

Hydrix Limited reports a robust quarter with $3.35 million in sales, a 7% revenue increase, and a strong international client base, while advancing US market ventures.

Hydrix Limited will have its trading suspension lifted on 13 October 2025 following the release of its audited financial statements for FY2025. Investors await clarity on the company’s financial health as it returns to the ASX.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.